Read on for independent studies & clinical trials on Symprove
(Don't just take our word)
Study #1: A challenge test of Symprove vs. other probiotics on their ability to Arrive, Survive & Thrive
An independent study by Dr Simon Gaisford at University College London (UCL) School of Pharmacy tested Symprove and 7 market-leading probiotics.
The study subjected the products to three challenge tests to assess if the bacteria ARRIVED in a live state, SURVIVED stomach acid transit and THRIVED in the target area of the gut.
Symprove was the only product to pass all three tests.
Study #2: A study to establish the efficacy of Symprove in irritable bowel syndrome (IBS)
This independent study was carried out at King’s College London by Dr Guy Sisson and Professor Ingvar Bjarnason to establish the efficacy of Symprove in irritable bowel syndrome (IBS).
The study was carried out on 186 IBS sufferers, mostly with moderate to severe symptoms. They each receive either a daily dose of Symprove or an identical placebo liquid for three months.
It concluded that a statistical significant improvement in overall symptom severity (in pain, bowel habit and bloating), was seen in IBS sufferers who took Symprove.
Study #3: A study to assess Symprove's efficacy in Inflammatory Bowel Disease (IBD)
In this double-blind, placebo-controlled trial 80 adults aged between 18 and 65-years-old with ulcerative colitis (who were all in remission at the time of the study starting) were randomised to receive either Symprove or a matching placebo drink for one month.
The study was carried out by Dr Guy Sisson, Dr Bu Hayee and Professor Ingvar Bjarnason of Darent Valley Hospital and King’s College London.
Faecal calprotectin levels were measured before and after treatment. Reductions in calprotectin levels (intestinal inflammation) were observed in the majority (76%) of patients with ulcerative colitis. The decrease in intestinal inflammation was significantly greater than in the placebo group.
Study #4: A study on Symprove and Diverticular Disease (DD)
In this double-blind, placebo-controlled trial 120 adults with moderate to severe diverticular disease (DD) were randomised to receive either Symprove or a matching placebo drink for three months.
The independent study was carried out at Kings College Hospital London by Dr Savvas Papagrigoriadis and Professor Ingvar Bjarnason.
The study concluded that Symprove had a significant benefit in the following:
Reduced the frequency of constipation, diarrhoea, mucorrhea and back pain
Prevented an escalation in inflammatory activity in males
Was associated with fewer diverticulitis episodes in a subgroup of patients.
